| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.3 | 3e-16 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |